1.48
0.02 (1.37%)
| Penutupan Terdahulu | 1.46 |
| Buka | 1.49 |
| Jumlah Dagangan | 251,705 |
| Purata Dagangan (3B) | 408,828 |
| Modal Pasaran | 215,291,168 |
| Harga / Jualan (P/S) | 2.58 |
| Harga / Buku (P/B) | 7.62 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 27 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -66.84% |
| Margin Operasi (TTM) | -47.33% |
| EPS Cair (TTM) | -0.370 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 34.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 226.08% |
| Nisbah Semasa (MRQ) | 3.40 |
| Aliran Tunai Operasi (OCF TTM) | -56.84 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -43.44 M |
| Pulangan Atas Aset (ROA TTM) | -22.79% |
| Pulangan Atas Ekuiti (ROE TTM) | -331.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Bercampur | Bercampur | |
| Stok | Biodesix, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.83 |
|
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 48.62% |
| % Dimiliki oleh Institusi | 42.83% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Wilmington Savings Fund Society, Fsb | 30 Sep 2024 | 6,095,034 |
| Birchview Capital, Lp | 30 Sep 2024 | 5,541,176 |
| Silverarc Capital Management, Llc | 30 Sep 2024 | 3,561,094 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 01 Nov 2024 | Pengumuman | Biodesix Announces Third Quarter 2024 Results and Highlights |
| 29 Oct 2024 | Pengumuman | Biodesix to Participate in Three Investor Conferences in November |
| 18 Oct 2024 | Pengumuman | Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024 |
| 07 Oct 2024 | Pengumuman | Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |